Drugs / NEO 201
NEO 201
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03476681 | Jan 2019 → Jun 2026 overdue | cervical cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma | Precision Biologics, Inc | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEO 201 | “In each cycle subjects will receive 3 doses of NEO 201 and one dose of pembrolizumab.” NCT03476681 ↗ |
| Known as | H16c3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594482 ↗ |
| Known as | H16c3 antibody | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594482 ↗ |
| Known as | Monoclonal antibody neo-201 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594482 ↗ |
| Modality | Monoclonal antibody | “NEO201 is a humanized IgG1 monoclonal antibody (mAb) generated against tumor-associated antigens from patients with colorectal cancer.” PMID 36991390 ↗ Mar 2023 |
| Route | Intravenous | “NEO-201 was administered intravenously every two weeks in a 28-day cycle” PMID 36991390 ↗ Mar 2023 |